Journal of Clinical Oncology, Vol 12, 1272-1280, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients

JL Abbruzzese, MC Abbruzzese, KR Hess, MN Raber, R Lenzi and P Frost
Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas M.D. Anderson Cancer Center, Houston.

PURPOSE: To evaluate the natural history, validate previous observations, and identify prognostic factors in patients with unknown primary carcinoma (UPC). PATIENTS AND METHODS: Nine hundred twenty- seven consecutive patients referred to the M.D. Anderson Cancer Center with a preliminary diagnosis of UPC were prospectively identified. A standardized evaluation narrowed the study population to 657 patients with UPC. All data were recorded and computerized for storage, retrieval, and analysis. The primary end point for the study was survival, which was calculated from the first day of patient registration. Survival curves were estimated using the Kaplan-Meier method and compared using the Cox-Mantel log-rank test. To identify important prognostic factors, univariate and multivariate analyses were conducted. RESULTS: The demographics of the UPC patient population mirrored those of the general population of patients referred to our cancer center except for an excess of men among the UPC patients. Most patients had histologic or cytologic evidence of adenocarcinoma and had more than one organ site metastatically involved. Univariate and multivariate analyses identified numerous important prognostic factors with a significant influence on survival, including sex, number of organ sites involved, specific organ sites involved, and pathologic subtypes. CONCLUSION: This study validated previously identified important prognostic factors for survival in UPC. Additional variables that had an impact on survival were identified and the complex interaction of the factors was explored. As patient numbers increase, this database will be able to provide further analyses of patient subsets and potentially relate specific clinical features to the evolving molecular and biochemical understanding of these malignancies.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Pentheroudakis and N. Pavlidis Probing the unknown in cancer of unknown primary: which way is the right way? Ann. Onc., January 20, 2010; (2010) mdp609v1. [Full Text] [PDF]

				M. Kodaira, S. Takahashi, S. Yamada, K. Ueda, Y. Mishima, K. Takeuchi, N. Yamamoto, Y. Ishikawa, M. Yokoyama, T. Saotome, et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy Ann. Onc., December 17, 2009; (2009) mdp583v1. [Abstract] [Full Text] [PDF]

				H. M. Horlings, R. K. van Laar, J.-M. Kerst, H. H. Helgason, J. Wesseling, J. J.M. van der Hoeven, M. O. Warmoes, A. Floore, A. Witteveen, J. Lahti-Domenici, et al. Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary J. Clin. Oncol., September 20, 2008; 26(27): 4435 - 4441. [Abstract] [Full Text] [PDF]

				C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth, D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, and F. A. Greco Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network J. Clin. Oncol., May 1, 2007; 25(13): 1747 - 1752. [Abstract] [Full Text] [PDF]

				U Joshi, J J M van der Hoeven, E F I Comans, G J Herder, G J J Teule, and O S Hoekstra In search of an unknown primary tumour presenting with extracervical metastases: the diagnostic performance of FDG-PET Br. J. Radiol., December 1, 2004; 77(924): 1000 - 1006. [Abstract] [Full Text] [PDF]

				R. C. Delgado-Bolton, C. Fernandez-Perez, A. Gonzalez-Mate, and J. L. Carreras Meta-Analysis of the Performance of 18F-FDG PET in Primary Tumor Detection in Unknown Primary Tumors J. Nucl. Med., August 1, 2003; 44(8): 1301 - 1314. [Abstract] [Full Text] [PDF]

				O. Schmidt-Kittler, T. Ragg, A. Daskalakis, M. Granzow, A. Ahr, T. J. F. Blankenstein, M. Kaufmann, J. Diebold, H. Arnholdt, P. Muller, et al. From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression PNAS, June 24, 2003; 100(13): 7737 - 7742. [Abstract] [Full Text] [PDF]

				G Antunes, E Neville, J Duffy, and N Ali BTS guidelines for the management of malignant pleural effusions Thorax, May 1, 2003; 58(90002): ii29 - 38. [Full Text]

				A. J. van de Wouw, R. L. H. Jansen, E. J. M. Speel, and H. F. P. Hillen The unknown biology of the unknown primary tumour: a literature review Ann. Onc., February 1, 2003; 14(2): 191 - 196. [Abstract] [Full Text] [PDF]

				S. Culine, A. Kramar, M. Saghatchian, R. Bugat, T. Lesimple, A. Lortholary, Y. Merrouche, A. Laplanche, and K. Fizazi Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site J. Clin. Oncol., December 15, 2002; 20(24): 4679 - 4683. [Abstract] [Full Text] [PDF]

				G ANTUNES and E NEVILLE Management of malignant pleural effusions Thorax, December 1, 2000; 55(12): 981 - 983. [Full Text]

				H F P Hillen Unknown primary tumours Postgrad. Med. J., November 1, 2000; 76(901): 690 - 693. [Abstract] [Full Text]

				K. R. Hess, M. C. Abbruzzese, R. Lenzi, M. N. Raber, and J. L. Abbruzzese Classification and Regression Tree Analysis of 1000 Consecutive Patients with Unknown Primary Carcinoma Clin. Cancer Res., November 1, 1999; 5(11): 3403 - 3410. [Abstract] [Full Text] [PDF]

				E. Briasoulis and N. Pavlidis Cancer of Unknown Primary Origin Oncologist, June 1, 1997; 2(3): 142 - 152. [Abstract] [Full Text] [PDF]